

Global Targeted Drug for Blood Cancers Market Growth 2024-2030

<https://marketpublishers.com/r/G011A00CECC3EN.html>

Date: July 2024

Pages: 142

Price: US\$ 3,660.00 (Single User License)

ID: G011A00CECC3EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Blood cancers (Leukemia) is a malignant clonal disease of hematopoietic stem cells. According to the degree of differentiation and maturity of leukemia cells and the natural history of the disease, leukemia is divided into two categories: acute leukemia (AL) and chronic leukemia (CL). Secondly, AL can be divided into acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) based on the mainly affected cell series. CL is divided into chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML, also known as chronic myelogenous leukemia) and rare types of leukemia. In the past decade or so, targeted drugs have made many breakthrough achievements in the clinical treatment of leukemia.

Targeted drugs for blood cancers are a class of pharmaceuticals designed to specifically target and attack cancer cells while minimizing harm to healthy cells. These drugs work by interfering with specific molecules or pathways that are crucial for cancer cell growth and survival. Examples of targeted drugs for blood cancers include monoclonal antibodies, small molecule inhibitors, and immunotherapies, which may target proteins on the surface of cancer cells, enzymes involved in cell signaling pathways, or immune checkpoints. By selectively targeting cancer cells, these drugs offer the potential for more effective treatment with fewer side effects compared to traditional chemotherapy. Targeted drugs have revolutionized the treatment landscape for blood cancers, offering new options for patients and improving outcomes.

As a new trend in the treatment of leukemia, gene-targeted drugs will see more research and development in the future. Although this drug still has some problems, such as high price, drug resistance, etc., with the continuous advancement of science

and technology and the continuous progress of medicine, it is believed that gene-targeted drugs will become an important means of treating leukemia.

The global Targeted Drug for Blood Cancers market size is projected to grow from US\$ million in 2024 to US\$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the "Targeted Drug for Blood Cancers Industry Forecast" looks at past sales and reviews total world Targeted Drug for Blood Cancers sales in 2023, providing a comprehensive analysis by region and market sector of projected Targeted Drug for Blood Cancers sales for 2024 through 2030. With Targeted Drug for Blood Cancers sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Targeted Drug for Blood Cancers industry.

This Insight Report provides a comprehensive analysis of the global Targeted Drug for Blood Cancers landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Targeted Drug for Blood Cancers portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Targeted Drug for Blood Cancers market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Drug for Blood Cancers and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drug for Blood Cancers.

Leukemia occurs most often in adults older than 55 years, but it is the most common cancer in children younger than 15 years. Among adults, the most common types are CLL (35%) and AML (32%). Among children and teens, ALL is the most common, accounting for 75% of pediatric leukemia cases.

Globally, an estimated 440,000 new cases of leukemia are diagnosed each year along with 310,000 deaths. There will be an estimated 60,000 new cases of leukemia in the United States in 2023, and more than 24,000 related deaths. Survival rates vary

substantially by leukemia subtype, ranging from a current five-year relative survival rate of 27% for adults diagnosed with AML to 86% for those with CLL, and 66% for children, adolescents, and young adults diagnosed with AML to 92% for those with ALL. In 2018, there are an estimated 381,774 people living with or in remission from leukemia in the United States. As the burden of leukemia grows, there will be a corresponding increase in the demand for effective treatment options, including targeted drugs.

The development of targeted drugs has transformed the treatment landscape for leukemia, offering improved efficacy and safety compared to traditional chemotherapy. Patients and healthcare providers increasingly prefer targeted therapies due to their ability to selectively attack cancer cells while sparing healthy tissues, leading to higher demand for these drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drug for Blood Cancers market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Monoclonal Antibodies

Small-Molecule Drugs

Segmentation by Application:

Acute Myeloid Leukemia (AML)

Chronic Myeloid Leukemia (CML)

Acute Lymphoblastic Leukemia (ALL)

Chronic Lymphocytic Leukemia (CLL)

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Novartis Pharms

Bristol-Myers Squibb

IL-Yang Pharms

Pfizer

Takeda Oncology

Johnson & Johnson

Gilead Sciences

Abbvie

Genentech

Sanofi

Amgen

Roche

GlaxoSmithKline

AstraZeneca

BeiGene

Eli Lilly

Merck

Key Questions Addressed in this Report

What is the 10-year outlook for the global Targeted Drug for Blood Cancers market?

What factors are driving Targeted Drug for Blood Cancers market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Targeted Drug for Blood Cancers market opportunities vary by end market size?

How does Targeted Drug for Blood Cancers break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Targeted Drug for Blood Cancers Annual Sales 2019-2030
 - 2.1.2 World Current & Future Analysis for Targeted Drug for Blood Cancers by Geographic Region, 2019, 2023 & 2030
 - 2.1.3 World Current & Future Analysis for Targeted Drug for Blood Cancers by Country/Region, 2019, 2023 & 2030
- 2.2 Targeted Drug for Blood Cancers Segment by Type
 - 2.2.1 Monoclonal Antibodies
 - 2.2.2 Small-Molecule Drugs
- 2.3 Targeted Drug for Blood Cancers Sales by Type
 - 2.3.1 Global Targeted Drug for Blood Cancers Sales Market Share by Type (2019-2024)
 - 2.3.2 Global Targeted Drug for Blood Cancers Revenue and Market Share by Type (2019-2024)
 - 2.3.3 Global Targeted Drug for Blood Cancers Sale Price by Type (2019-2024)
- 2.4 Targeted Drug for Blood Cancers Segment by Application
 - 2.4.1 Acute Myeloid Leukemia (AML)
 - 2.4.2 Chronic Myeloid Leukemia (CML)
 - 2.4.3 Acute Lymphoblastic Leukemia (ALL)
 - 2.4.4 Chronic Lymphocytic Leukemia (CLL)
- 2.5 Targeted Drug for Blood Cancers Sales by Application
 - 2.5.1 Global Targeted Drug for Blood Cancers Sale Market Share by Application (2019-2024)
 - 2.5.2 Global Targeted Drug for Blood Cancers Revenue and Market Share by

Application (2019-2024)

2.5.3 Global Targeted Drug for Blood Cancers Sale Price by Application (2019-2024)

3 GLOBAL BY COMPANY

3.1 Global Targeted Drug for Blood Cancers Breakdown Data by Company

3.1.1 Global Targeted Drug for Blood Cancers Annual Sales by Company (2019-2024)

3.1.2 Global Targeted Drug for Blood Cancers Sales Market Share by Company (2019-2024)

3.2 Global Targeted Drug for Blood Cancers Annual Revenue by Company (2019-2024)

3.2.1 Global Targeted Drug for Blood Cancers Revenue by Company (2019-2024)

3.2.2 Global Targeted Drug for Blood Cancers Revenue Market Share by Company (2019-2024)

3.3 Global Targeted Drug for Blood Cancers Sale Price by Company

3.4 Key Manufacturers Targeted Drug for Blood Cancers Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Targeted Drug for Blood Cancers Product Location Distribution

3.4.2 Players Targeted Drug for Blood Cancers Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR TARGETED DRUG FOR BLOOD CANCERS BY GEOGRAPHIC REGION

4.1 World Historic Targeted Drug for Blood Cancers Market Size by Geographic Region (2019-2024)

4.1.1 Global Targeted Drug for Blood Cancers Annual Sales by Geographic Region (2019-2024)

4.1.2 Global Targeted Drug for Blood Cancers Annual Revenue by Geographic Region (2019-2024)

4.2 World Historic Targeted Drug for Blood Cancers Market Size by Country/Region (2019-2024)

4.2.1 Global Targeted Drug for Blood Cancers Annual Sales by Country/Region (2019-2024)

4.2.2 Global Targeted Drug for Blood Cancers Annual Revenue by Country/Region

(2019-2024)

4.3 Americas Targeted Drug for Blood Cancers Sales Growth

4.4 APAC Targeted Drug for Blood Cancers Sales Growth

4.5 Europe Targeted Drug for Blood Cancers Sales Growth

4.6 Middle East & Africa Targeted Drug for Blood Cancers Sales Growth

5 AMERICAS

5.1 Americas Targeted Drug for Blood Cancers Sales by Country

5.1.1 Americas Targeted Drug for Blood Cancers Sales by Country (2019-2024)

5.1.2 Americas Targeted Drug for Blood Cancers Revenue by Country (2019-2024)

5.2 Americas Targeted Drug for Blood Cancers Sales by Type (2019-2024)

5.3 Americas Targeted Drug for Blood Cancers Sales by Application (2019-2024)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Targeted Drug for Blood Cancers Sales by Region

6.1.1 APAC Targeted Drug for Blood Cancers Sales by Region (2019-2024)

6.1.2 APAC Targeted Drug for Blood Cancers Revenue by Region (2019-2024)

6.2 APAC Targeted Drug for Blood Cancers Sales by Type (2019-2024)

6.3 APAC Targeted Drug for Blood Cancers Sales by Application (2019-2024)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Targeted Drug for Blood Cancers by Country

7.1.1 Europe Targeted Drug for Blood Cancers Sales by Country (2019-2024)

7.1.2 Europe Targeted Drug for Blood Cancers Revenue by Country (2019-2024)

7.2 Europe Targeted Drug for Blood Cancers Sales by Type (2019-2024)

7.3 Europe Targeted Drug for Blood Cancers Sales by Application (2019-2024)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Targeted Drug for Blood Cancers by Country

8.1.1 Middle East & Africa Targeted Drug for Blood Cancers Sales by Country (2019-2024)

8.1.2 Middle East & Africa Targeted Drug for Blood Cancers Revenue by Country (2019-2024)

8.2 Middle East & Africa Targeted Drug for Blood Cancers Sales by Type (2019-2024)

8.3 Middle East & Africa Targeted Drug for Blood Cancers Sales by Application (2019-2024)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Targeted Drug for Blood Cancers

10.3 Manufacturing Process Analysis of Targeted Drug for Blood Cancers

10.4 Industry Chain Structure of Targeted Drug for Blood Cancers

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

- 11.1.1 Direct Channels
- 11.1.2 Indirect Channels
- 11.2 Targeted Drug for Blood Cancers Distributors
- 11.3 Targeted Drug for Blood Cancers Customer

12 WORLD FORECAST REVIEW FOR TARGETED DRUG FOR BLOOD CANCERS BY GEOGRAPHIC REGION

- 12.1 Global Targeted Drug for Blood Cancers Market Size Forecast by Region
 - 12.1.1 Global Targeted Drug for Blood Cancers Forecast by Region (2025-2030)
 - 12.1.2 Global Targeted Drug for Blood Cancers Annual Revenue Forecast by Region (2025-2030)
- 12.2 Americas Forecast by Country (2025-2030)
- 12.3 APAC Forecast by Region (2025-2030)
- 12.4 Europe Forecast by Country (2025-2030)
- 12.5 Middle East & Africa Forecast by Country (2025-2030)
- 12.6 Global Targeted Drug for Blood Cancers Forecast by Type (2025-2030)
- 12.7 Global Targeted Drug for Blood Cancers Forecast by Application (2025-2030)

13 KEY PLAYERS ANALYSIS

- 13.1 Novartis Pharms
 - 13.1.1 Novartis Pharms Company Information
 - 13.1.2 Novartis Pharms Targeted Drug for Blood Cancers Product Portfolios and Specifications
 - 13.1.3 Novartis Pharms Targeted Drug for Blood Cancers Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.1.4 Novartis Pharms Main Business Overview
 - 13.1.5 Novartis Pharms Latest Developments
- 13.2 Bristol-Myers Squibb
 - 13.2.1 Bristol-Myers Squibb Company Information
 - 13.2.2 Bristol-Myers Squibb Targeted Drug for Blood Cancers Product Portfolios and Specifications
 - 13.2.3 Bristol-Myers Squibb Targeted Drug for Blood Cancers Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.2.4 Bristol-Myers Squibb Main Business Overview
 - 13.2.5 Bristol-Myers Squibb Latest Developments
- 13.3 IL-Yang Pharms
 - 13.3.1 IL-Yang Pharms Company Information

13.3.2 IL-Yang Pharms Targeted Drug for Blood Cancers Product Portfolios and Specifications

13.3.3 IL-Yang Pharms Targeted Drug for Blood Cancers Sales, Revenue, Price and Gross Margin (2019-2024)

13.3.4 IL-Yang Pharms Main Business Overview

13.3.5 IL-Yang Pharms Latest Developments

13.4 Pfizer

13.4.1 Pfizer Company Information

13.4.2 Pfizer Targeted Drug for Blood Cancers Product Portfolios and Specifications

13.4.3 Pfizer Targeted Drug for Blood Cancers Sales, Revenue, Price and Gross Margin (2019-2024)

13.4.4 Pfizer Main Business Overview

13.4.5 Pfizer Latest Developments

13.5 Takeda Oncology

13.5.1 Takeda Oncology Company Information

13.5.2 Takeda Oncology Targeted Drug for Blood Cancers Product Portfolios and Specifications

13.5.3 Takeda Oncology Targeted Drug for Blood Cancers Sales, Revenue, Price and Gross Margin (2019-2024)

13.5.4 Takeda Oncology Main Business Overview

13.5.5 Takeda Oncology Latest Developments

13.6 Johnson & Johnson

13.6.1 Johnson & Johnson Company Information

13.6.2 Johnson & Johnson Targeted Drug for Blood Cancers Product Portfolios and Specifications

13.6.3 Johnson & Johnson Targeted Drug for Blood Cancers Sales, Revenue, Price and Gross Margin (2019-2024)

13.6.4 Johnson & Johnson Main Business Overview

13.6.5 Johnson & Johnson Latest Developments

13.7 Gilead Sciences

13.7.1 Gilead Sciences Company Information

13.7.2 Gilead Sciences Targeted Drug for Blood Cancers Product Portfolios and Specifications

13.7.3 Gilead Sciences Targeted Drug for Blood Cancers Sales, Revenue, Price and Gross Margin (2019-2024)

13.7.4 Gilead Sciences Main Business Overview

13.7.5 Gilead Sciences Latest Developments

13.8 Abbvie

13.8.1 Abbvie Company Information

- 13.8.2 Abbvie Targeted Drug for Blood Cancers Product Portfolios and Specifications
- 13.8.3 Abbvie Targeted Drug for Blood Cancers Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.8.4 Abbvie Main Business Overview
- 13.8.5 Abbvie Latest Developments
- 13.9 Genentech
 - 13.9.1 Genentech Company Information
 - 13.9.2 Genentech Targeted Drug for Blood Cancers Product Portfolios and Specifications
 - 13.9.3 Genentech Targeted Drug for Blood Cancers Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.9.4 Genentech Main Business Overview
 - 13.9.5 Genentech Latest Developments
- 13.10 Sanofi
 - 13.10.1 Sanofi Company Information
 - 13.10.2 Sanofi Targeted Drug for Blood Cancers Product Portfolios and Specifications
 - 13.10.3 Sanofi Targeted Drug for Blood Cancers Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.10.4 Sanofi Main Business Overview
 - 13.10.5 Sanofi Latest Developments
- 13.11 Amgen
 - 13.11.1 Amgen Company Information
 - 13.11.2 Amgen Targeted Drug for Blood Cancers Product Portfolios and Specifications
 - 13.11.3 Amgen Targeted Drug for Blood Cancers Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.11.4 Amgen Main Business Overview
 - 13.11.5 Amgen Latest Developments
- 13.12 Roche
 - 13.12.1 Roche Company Information
 - 13.12.2 Roche Targeted Drug for Blood Cancers Product Portfolios and Specifications
 - 13.12.3 Roche Targeted Drug for Blood Cancers Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.12.4 Roche Main Business Overview
 - 13.12.5 Roche Latest Developments
- 13.13 GlaxoSmithKline
 - 13.13.1 GlaxoSmithKline Company Information
 - 13.13.2 GlaxoSmithKline Targeted Drug for Blood Cancers Product Portfolios and Specifications
 - 13.13.3 GlaxoSmithKline Targeted Drug for Blood Cancers Sales, Revenue, Price and

Gross Margin (2019-2024)

13.13.4 GlaxoSmithKline Main Business Overview

13.13.5 GlaxoSmithKline Latest Developments

13.14 AstraZeneca

13.14.1 AstraZeneca Company Information

13.14.2 AstraZeneca Targeted Drug for Blood Cancers Product Portfolios and Specifications

13.14.3 AstraZeneca Targeted Drug for Blood Cancers Sales, Revenue, Price and Gross Margin (2019-2024)

13.14.4 AstraZeneca Main Business Overview

13.14.5 AstraZeneca Latest Developments

13.15 BeiGene

13.15.1 BeiGene Company Information

13.15.2 BeiGene Targeted Drug for Blood Cancers Product Portfolios and Specifications

13.15.3 BeiGene Targeted Drug for Blood Cancers Sales, Revenue, Price and Gross Margin (2019-2024)

13.15.4 BeiGene Main Business Overview

13.15.5 BeiGene Latest Developments

13.16 Eli Lilly

13.16.1 Eli Lilly Company Information

13.16.2 Eli Lilly Targeted Drug for Blood Cancers Product Portfolios and Specifications

13.16.3 Eli Lilly Targeted Drug for Blood Cancers Sales, Revenue, Price and Gross Margin (2019-2024)

13.16.4 Eli Lilly Main Business Overview

13.16.5 Eli Lilly Latest Developments

13.17 Merck

13.17.1 Merck Company Information

13.17.2 Merck Targeted Drug for Blood Cancers Product Portfolios and Specifications

13.17.3 Merck Targeted Drug for Blood Cancers Sales, Revenue, Price and Gross Margin (2019-2024)

13.17.4 Merck Main Business Overview

13.17.5 Merck Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Targeted Drug for Blood Cancers Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Table 2. Targeted Drug for Blood Cancers Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions)

Table 3. Major Players of Monoclonal Antibodies

Table 4. Major Players of Small-Molecule Drugs

Table 5. Global Targeted Drug for Blood Cancers Sales by Type (2019-2024) & (Units)

Table 6. Global Targeted Drug for Blood Cancers Sales Market Share by Type (2019-2024)

Table 7. Global Targeted Drug for Blood Cancers Revenue by Type (2019-2024) & (\$ million)

Table 8. Global Targeted Drug for Blood Cancers Revenue Market Share by Type (2019-2024)

Table 9. Global Targeted Drug for Blood Cancers Sale Price by Type (2019-2024) & (US\$/Unit)

Table 10. Global Targeted Drug for Blood Cancers Sale by Application (2019-2024) & (Units)

Table 11. Global Targeted Drug for Blood Cancers Sale Market Share by Application (2019-2024)

Table 12. Global Targeted Drug for Blood Cancers Revenue by Application (2019-2024) & (\$ million)

Table 13. Global Targeted Drug for Blood Cancers Revenue Market Share by Application (2019-2024)

Table 14. Global Targeted Drug for Blood Cancers Sale Price by Application (2019-2024) & (US\$/Unit)

Table 15. Global Targeted Drug for Blood Cancers Sales by Company (2019-2024) & (Units)

Table 16. Global Targeted Drug for Blood Cancers Sales Market Share by Company (2019-2024)

Table 17. Global Targeted Drug for Blood Cancers Revenue by Company (2019-2024) & (\$ millions)

Table 18. Global Targeted Drug for Blood Cancers Revenue Market Share by Company (2019-2024)

Table 19. Global Targeted Drug for Blood Cancers Sale Price by Company (2019-2024) & (US\$/Unit)

Table 20. Key Manufacturers Targeted Drug for Blood Cancers Producing Area Distribution and Sales Area

Table 21. Players Targeted Drug for Blood Cancers Products Offered

Table 22. Targeted Drug for Blood Cancers Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

Table 23. New Products and Potential Entrants

Table 24. Market M&A Activity & Strategy

Table 25. Global Targeted Drug for Blood Cancers Sales by Geographic Region (2019-2024) & (Units)

Table 26. Global Targeted Drug for Blood Cancers Sales Market Share Geographic Region (2019-2024)

Table 27. Global Targeted Drug for Blood Cancers Revenue by Geographic Region (2019-2024) & (\$ millions)

Table 28. Global Targeted Drug for Blood Cancers Revenue Market Share by Geographic Region (2019-2024)

Table 29. Global Targeted Drug for Blood Cancers Sales by Country/Region (2019-2024) & (Units)

Table 30. Global Targeted Drug for Blood Cancers Sales Market Share by Country/Region (2019-2024)

Table 31. Global Targeted Drug for Blood Cancers Revenue by Country/Region (2019-2024) & (\$ millions)

Table 32. Global Targeted Drug for Blood Cancers Revenue Market Share by Country/Region (2019-2024)

Table 33. Americas Targeted Drug for Blood Cancers Sales by Country (2019-2024) & (Units)

Table 34. Americas Targeted Drug for Blood Cancers Sales Market Share by Country (2019-2024)

Table 35. Americas Targeted Drug for Blood Cancers Revenue by Country (2019-2024) & (\$ millions)

Table 36. Americas Targeted Drug for Blood Cancers Sales by Type (2019-2024) & (Units)

Table 37. Americas Targeted Drug for Blood Cancers Sales by Application (2019-2024) & (Units)

Table 38. APAC Targeted Drug for Blood Cancers Sales by Region (2019-2024) & (Units)

Table 39. APAC Targeted Drug for Blood Cancers Sales Market Share by Region (2019-2024)

Table 40. APAC Targeted Drug for Blood Cancers Revenue by Region (2019-2024) & (\$ millions)

Table 41. APAC Targeted Drug for Blood Cancers Sales by Type (2019-2024) & (Units)

Table 42. APAC Targeted Drug for Blood Cancers Sales by Application (2019-2024) & (Units)

Table 43. Europe Targeted Drug for Blood Cancers Sales by Country (2019-2024) & (Units)

Table 44. Europe Targeted Drug for Blood Cancers Revenue by Country (2019-2024) & (\$ millions)

Table 45. Europe Targeted Drug for Blood Cancers Sales by Type (2019-2024) & (Units)

Table 46. Europe Targeted Drug for Blood Cancers Sales by Application (2019-2024) & (Units)

Table 47. Middle East & Africa Targeted Drug for Blood Cancers Sales by Country (2019-2024) & (Units)

Table 48. Middle East & Africa Targeted Drug for Blood Cancers Revenue Market Share by Country (2019-2024)

Table 49. Middle East & Africa Targeted Drug for Blood Cancers Sales by Type (2019-2024) & (Units)

Table 50. Middle East & Africa Targeted Drug for Blood Cancers Sales by Application (2019-2024) & (Units)

Table 51. Key Market Drivers & Growth Opportunities of Targeted Drug for Blood Cancers

Table 52. Key Market Challenges & Risks of Targeted Drug for Blood Cancers

Table 53. Key Industry Trends of Targeted Drug for Blood Cancers

Table 54. Targeted Drug for Blood Cancers Raw Material

Table 55. Key Suppliers of Raw Materials

Table 56. Targeted Drug for Blood Cancers Distributors List

Table 57. Targeted Drug for Blood Cancers Customer List

Table 58. Global Targeted Drug for Blood Cancers Sales Forecast by Region (2025-2030) & (Units)

Table 59. Global Targeted Drug for Blood Cancers Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 60. Americas Targeted Drug for Blood Cancers Sales Forecast by Country (2025-2030) & (Units)

Table 61. Americas Targeted Drug for Blood Cancers Annual Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 62. APAC Targeted Drug for Blood Cancers Sales Forecast by Region (2025-2030) & (Units)

Table 63. APAC Targeted Drug for Blood Cancers Annual Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 64. Europe Targeted Drug for Blood Cancers Sales Forecast by Country (2025-2030) & (Units)

Table 65. Europe Targeted Drug for Blood Cancers Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 66. Middle East & Africa Targeted Drug for Blood Cancers Sales Forecast by Country (2025-2030) & (Units)

Table 67. Middle East & Africa Targeted Drug for Blood Cancers Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 68. Global Targeted Drug for Blood Cancers Sales Forecast by Type (2025-2030) & (Units)

Table 69. Global Targeted Drug for Blood Cancers Revenue Forecast by Type (2025-2030) & (\$ millions)

Table 70. Global Targeted Drug for Blood Cancers Sales Forecast by Application (2025-2030) & (Units)

Table 71. Global Targeted Drug for Blood Cancers Revenue Forecast by Application (2025-2030) & (\$ millions)

Table 72. Novartis Pharms Basic Information, Targeted Drug for Blood Cancers Manufacturing Base, Sales Area and Its Competitors

Table 73. Novartis Pharms Targeted Drug for Blood Cancers Product Portfolios and Specifications

Table 74. Novartis Pharms Targeted Drug for Blood Cancers Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 75. Novartis Pharms Main Business

Table 76. Novartis Pharms Latest Developments

Table 77. Bristol-Myers Squibb Basic Information, Targeted Drug for Blood Cancers Manufacturing Base, Sales Area and Its Competitors

Table 78. Bristol-Myers Squibb Targeted Drug for Blood Cancers Product Portfolios and Specifications

Table 79. Bristol-Myers Squibb Targeted Drug for Blood Cancers Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 80. Bristol-Myers Squibb Main Business

Table 81. Bristol-Myers Squibb Latest Developments

Table 82. IL-Yang Pharms Basic Information, Targeted Drug for Blood Cancers Manufacturing Base, Sales Area and Its Competitors

Table 83. IL-Yang Pharms Targeted Drug for Blood Cancers Product Portfolios and Specifications

Table 84. IL-Yang Pharms Targeted Drug for Blood Cancers Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 85. IL-Yang Pharms Main Business

- Table 86. IL-Yang Pharms Latest Developments
- Table 87. Pfizer Basic Information, Targeted Drug for Blood Cancers Manufacturing Base, Sales Area and Its Competitors
- Table 88. Pfizer Targeted Drug for Blood Cancers Product Portfolios and Specifications
- Table 89. Pfizer Targeted Drug for Blood Cancers Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)
- Table 90. Pfizer Main Business
- Table 91. Pfizer Latest Developments
- Table 92. Takeda Oncology Basic Information, Targeted Drug for Blood Cancers Manufacturing Base, Sales Area and Its Competitors
- Table 93. Takeda Oncology Targeted Drug for Blood Cancers Product Portfolios and Specifications
- Table 94. Takeda Oncology Targeted Drug for Blood Cancers Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)
- Table 95. Takeda Oncology Main Business
- Table 96. Takeda Oncology Latest Developments
- Table 97. Johnson & Johnson Basic Information, Targeted Drug for Blood Cancers Manufacturing Base, Sales Area and Its Competitors
- Table 98. Johnson & Johnson Targeted Drug for Blood Cancers Product Portfolios and Specifications
- Table 99. Johnson & Johnson Targeted Drug for Blood Cancers Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)
- Table 100. Johnson & Johnson Main Business
- Table 101. Johnson & Johnson Latest Developments
- Table 102. Gilead Sciences Basic Information, Targeted Drug for Blood Cancers Manufacturing Base, Sales Area and Its Competitors
- Table 103. Gilead Sciences Targeted Drug for Blood Cancers Product Portfolios and Specifications
- Table 104. Gilead Sciences Targeted Drug for Blood Cancers Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)
- Table 105. Gilead Sciences Main Business
- Table 106. Gilead Sciences Latest Developments
- Table 107. Abbvie Basic Information, Targeted Drug for Blood Cancers Manufacturing Base, Sales Area and Its Competitors
- Table 108. Abbvie Targeted Drug for Blood Cancers Product Portfolios and Specifications
- Table 109. Abbvie Targeted Drug for Blood Cancers Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)
- Table 110. Abbvie Main Business

Table 111. Abbvie Latest Developments

Table 112. Genentech Basic Information, Targeted Drug for Blood Cancers Manufacturing Base, Sales Area and Its Competitors

Table 113. Genentech Targeted Drug for Blood Cancers Product Portfolios and Specifications

Table 114. Genentech Targeted Drug for Blood Cancers Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 115. Genentech Main Business

Table 116. Genentech Latest Developments

Table 117. Sanofi Basic Information, Targeted Drug for Blood Cancers Manufacturing Base, Sales Area and Its Competitors

Table 118. Sanofi Targeted Drug for Blood Cancers Product Portfolios and Specifications

Table 119. Sanofi Targeted Drug for Blood Cancers Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 120. Sanofi Main Business

Table 121. Sanofi Latest Developments

Table 122. Amgen Basic Information, Targeted Drug for Blood Cancers Manufacturing Base, Sales Area and Its Competitors

Table 123. Amgen Targeted Drug for Blood Cancers Product Portfolios and Specifications

Table 124. Amgen Targeted Drug for Blood Cancers Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 125. Amgen Main Business

Table 126. Amgen Latest Developments

Table 127. Roche Basic Information, Targeted Drug for Blood Cancers Manufacturing Base, Sales Area and Its Competitors

Table 128. Roche Targeted Drug for Blood Cancers Product Portfolios and Specifications

Table 129. Roche Targeted Drug for Blood Cancers Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 130. Roche Main Business

Table 131. Roche Latest Developments

Table 132. GlaxoSmithKline Basic Information, Targeted Drug for Blood Cancers Manufacturing Base, Sales Area and Its Competitors

Table 133. GlaxoSmithKline Targeted Drug for Blood Cancers Product Portfolios and Specifications

Table 134. GlaxoSmithKline Targeted Drug for Blood Cancers Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 135. GlaxoSmithKline Main Business

Table 136. GlaxoSmithKline Latest Developments

Table 137. AstraZeneca Basic Information, Targeted Drug for Blood Cancers Manufacturing Base, Sales Area and Its Competitors

Table 138. AstraZeneca Targeted Drug for Blood Cancers Product Portfolios and Specifications

Table 139. AstraZeneca Targeted Drug for Blood Cancers Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 140. AstraZeneca Main Business

Table 141. AstraZeneca Latest Developments

Table 142. BeiGene Basic Information, Targeted Drug for Blood Cancers Manufacturing Base, Sales Area and Its Competitors

Table 143. BeiGene Targeted Drug for Blood Cancers Product Portfolios and Specifications

Table 144. BeiGene Targeted Drug for Blood Cancers Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 145. BeiGene Main Business

Table 146. BeiGene Latest Developments

Table 147. Eli Lilly Basic Information, Targeted Drug for Blood Cancers Manufacturing Base, Sales Area and Its Competitors

Table 148. Eli Lilly Targeted Drug for Blood Cancers Product Portfolios and Specifications

Table 149. Eli Lilly Targeted Drug for Blood Cancers Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 150. Eli Lilly Main Business

Table 151. Eli Lilly Latest Developments

Table 152. Merck Basic Information, Targeted Drug for Blood Cancers Manufacturing Base, Sales Area and Its Competitors

Table 153. Merck Targeted Drug for Blood Cancers Product Portfolios and Specifications

Table 154. Merck Targeted Drug for Blood Cancers Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 155. Merck Main Business

Table 156. Merck Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Targeted Drug for Blood Cancers
- Figure 2. Targeted Drug for Blood Cancers Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Targeted Drug for Blood Cancers Sales Growth Rate 2019-2030 (Units)
- Figure 7. Global Targeted Drug for Blood Cancers Revenue Growth Rate 2019-2030 (\$ millions)
- Figure 8. Targeted Drug for Blood Cancers Sales by Geographic Region (2019, 2023 & 2030) & (\$ millions)
- Figure 9. Targeted Drug for Blood Cancers Sales Market Share by Country/Region (2023)
- Figure 10. Targeted Drug for Blood Cancers Sales Market Share by Country/Region (2019, 2023 & 2030)
- Figure 11. Product Picture of Monoclonal Antibodies
- Figure 12. Product Picture of Small-Molecule Drugs
- Figure 13. Global Targeted Drug for Blood Cancers Sales Market Share by Type in 2023
- Figure 14. Global Targeted Drug for Blood Cancers Revenue Market Share by Type (2019-2024)
- Figure 15. Targeted Drug for Blood Cancers Consumed in Acute Myeloid Leukemia (AML)
- Figure 16. Global Targeted Drug for Blood Cancers Market: Acute Myeloid Leukemia (AML) (2019-2024) & (Units)
- Figure 17. Targeted Drug for Blood Cancers Consumed in Chronic Myeloid Leukemia (CML)
- Figure 18. Global Targeted Drug for Blood Cancers Market: Chronic Myeloid Leukemia (CML) (2019-2024) & (Units)
- Figure 19. Targeted Drug for Blood Cancers Consumed in Acute Lymphoblastic Leukemia (ALL)
- Figure 20. Global Targeted Drug for Blood Cancers Market: Acute Lymphoblastic Leukemia (ALL) (2019-2024) & (Units)
- Figure 21. Targeted Drug for Blood Cancers Consumed in Chronic Lymphocytic Leukemia (CLL)

Figure 22. Global Targeted Drug for Blood Cancers Market: Chronic Lymphocytic Leukemia (CLL) (2019-2024) & (Units)

Figure 23. Global Targeted Drug for Blood Cancers Sale Market Share by Application (2023)

Figure 24. Global Targeted Drug for Blood Cancers Revenue Market Share by Application in 2023

Figure 25. Targeted Drug for Blood Cancers Sales by Company in 2023 (Units)

Figure 26. Global Targeted Drug for Blood Cancers Sales Market Share by Company in 2023

Figure 27. Targeted Drug for Blood Cancers Revenue by Company in 2023 (\$ millions)

Figure 28. Global Targeted Drug for Blood Cancers Revenue Market Share by Company in 2023

Figure 29. Global Targeted Drug for Blood Cancers Sales Market Share by Geographic Region (2019-2024)

Figure 30. Global Targeted Drug for Blood Cancers Revenue Market Share by Geographic Region in 2023

Figure 31. Americas Targeted Drug for Blood Cancers Sales 2019-2024 (Units)

Figure 32. Americas Targeted Drug for Blood Cancers Revenue 2019-2024 (\$ millions)

Figure 33. APAC Targeted Drug for Blood Cancers Sales 2019-2024 (Units)

Figure 34. APAC Targeted Drug for Blood Cancers Revenue 2019-2024 (\$ millions)

Figure 35. Europe Targeted Drug for Blood Cancers Sales 2019-2024 (Units)

Figure 36. Europe Targeted Drug for Blood Cancers Revenue 2019-2024 (\$ millions)

Figure 37. Middle East & Africa Targeted Drug for Blood Cancers Sales 2019-2024 (Units)

Figure 38. Middle East & Africa Targeted Drug for Blood Cancers Revenue 2019-2024 (\$ millions)

Figure 39. Americas Targeted Drug for Blood Cancers Sales Market Share by Country in 2023

Figure 40. Americas Targeted Drug for Blood Cancers Revenue Market Share by Country (2019-2024)

Figure 41. Americas Targeted Drug for Blood Cancers Sales Market Share by Type (2019-2024)

Figure 42. Americas Targeted Drug for Blood Cancers Sales Market Share by Application (2019-2024)

Figure 43. United States Targeted Drug for Blood Cancers Revenue Growth 2019-2024 (\$ millions)

Figure 44. Canada Targeted Drug for Blood Cancers Revenue Growth 2019-2024 (\$ millions)

Figure 45. Mexico Targeted Drug for Blood Cancers Revenue Growth 2019-2024 (\$

millions)

Figure 46. Brazil Targeted Drug for Blood Cancers Revenue Growth 2019-2024 (\$ millions)

Figure 47. APAC Targeted Drug for Blood Cancers Sales Market Share by Region in 2023

Figure 48. APAC Targeted Drug for Blood Cancers Revenue Market Share by Region (2019-2024)

Figure 49. APAC Targeted Drug for Blood Cancers Sales Market Share by Type (2019-2024)

Figure 50. APAC Targeted Drug for Blood Cancers Sales Market Share by Application (2019-2024)

Figure 51. China Targeted Drug for Blood Cancers Revenue Growth 2019-2024 (\$ millions)

Figure 52. Japan Targeted Drug for Blood Cancers Revenue Growth 2019-2024 (\$ millions)

Figure 53. South Korea Targeted Drug for Blood Cancers Revenue Growth 2019-2024 (\$ millions)

Figure 54. Southeast Asia Targeted Drug for Blood Cancers Revenue Growth 2019-2024 (\$ millions)

Figure 55. India Targeted Drug for Blood Cancers Revenue Growth 2019-2024 (\$ millions)

Figure 56. Australia Targeted Drug for Blood Cancers Revenue Growth 2019-2024 (\$ millions)

Figure 57. China Taiwan Targeted Drug for Blood Cancers Revenue Growth 2019-2024 (\$ millions)

Figure 58. Europe Targeted Drug for Blood Cancers Sales Market Share by Country in 2023

Figure 59. Europe Targeted Drug for Blood Cancers Revenue Market Share by Country (2019-2024)

Figure 60. Europe Targeted Drug for Blood Cancers Sales Market Share by Type (2019-2024)

Figure 61. Europe Targeted Drug for Blood Cancers Sales Market Share by Application (2019-2024)

Figure 62. Germany Targeted Drug for Blood Cancers Revenue Growth 2019-2024 (\$ millions)

Figure 63. France Targeted Drug for Blood Cancers Revenue Growth 2019-2024 (\$ millions)

Figure 64. UK Targeted Drug for Blood Cancers Revenue Growth 2019-2024 (\$ millions)

Figure 65. Italy Targeted Drug for Blood Cancers Revenue Growth 2019-2024 (\$ millions)

Figure 66. Russia Targeted Drug for Blood Cancers Revenue Growth 2019-2024 (\$ millions)

Figure 67. Middle East & Africa Targeted Drug for Blood Cancers Sales Market Share by Country (2019-2024)

Figure 68. Middle East & Africa Targeted Drug for Blood Cancers Sales Market Share by Type (2019-2024)

Figure 69. Middle East & Africa Targeted Drug for Blood Cancers Sales Market Share by Application (2019-2024)

Figure 70. Egypt Targeted Drug for Blood Cancers Revenue Growth 2019-2024 (\$ millions)

Figure 71. South Africa Targeted Drug for Blood Cancers Revenue Growth 2019-2024 (\$ millions)

Figure 72. Israel Targeted Drug for Blood Cancers Revenue Growth 2019-2024 (\$ millions)

Figure 73. Turkey Targeted Drug for Blood Cancers Revenue Growth 2019-2024 (\$ millions)

Figure 74. GCC Countries Targeted Drug for Blood Cancers Revenue Growth 2019-2024 (\$ millions)

Figure 75. Manufacturing Cost Structure Analysis of Targeted Drug for Blood Cancers in 2023

Figure 76. Manufacturing Process Analysis of Targeted Drug for Blood Cancers

Figure 77. Industry Chain Structure of Targeted Drug for Blood Cancers

Figure 78. Channels of Distribution

Figure 79. Global Targeted Drug for Blood Cancers Sales Market Forecast by Region (2025-2030)

Figure 80. Global Targeted Drug for Blood Cancers Revenue Market Share Forecast by Region (2025-2030)

Figure 81. Global Targeted Drug for Blood Cancers Sales Market Share Forecast by Type (2025-2030)

Figure 82. Global Targeted Drug for Blood Cancers Revenue Market Share Forecast by Type (2025-2030)

Figure 83. Global Targeted Drug for Blood Cancers Sales Market Share Forecast by Application (2025-2030)

Figure 84. Global Targeted Drug for Blood Cancers Revenue Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Targeted Drug for Blood Cancers Market Growth 2024-2030

Product link: <https://marketpublishers.com/r/G011A00CECC3EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G011A00CECC3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970